➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Mallinckrodt
Harvard Business School
Express Scripts
Merck
Baxter

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

Patent: 6,702,850

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,702,850
Title: Multi-coated drug-eluting stent for antithrombosis and antirestenosis
Abstract:A stent having a multi-layered coating adhered to its surface which can prevent restenosis and thrombosis at the implant site. The stent coating is comprised of two layers. The first layer is a polymeric coating with one or more biologically active agent(s) dispersed therein. The second layer is comprised of a hydrophobic heparinized polymer that inhibits blood coagulation and provides a hydrophilic surface for reducing the friction between stent and lesion site. In preferred embodiments of the invention, the multi-layered stent is effective in deterring restenosis and thrombosis at the implant site. In these same preferred embodiments, the multi-layered stent is capable of reducing the burst release of the biologically active agents from the first layer and sustaining a release of an effective amount of these agents for a relatively extended period of time. Methods of applying the multi-layered coating to the stent surface are also part of this invention.
Inventor(s): Byun; Youngro (Seoul, KR), Yoon; Jung Han (Seoul, KR)
Assignee: Mediplex Corporation Korea (Seoul, KR)
Application Number:10/262,432
Patent Claims:see list of patent claims

Details for Patent 6,702,850

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial Mediplex Corporation Korea (Seoul, KR) 2039-02-26 RX search
Organon Usa Inc. TICE BCG bacillus calmette-guerin POWDER, FOR SUSPENSION 102821 1 1990-08-24   Start Trial Mediplex Corporation Korea (Seoul, KR) 2039-02-26 search
Chiron PROLEUKIN aldesleukin VIAL 103293 001 1992-05-05   Start Trial Mediplex Corporation Korea (Seoul, KR) 2039-02-26 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 001 1991-02-20   Start Trial Mediplex Corporation Korea (Seoul, KR) 2039-02-26 RX search
Amgen NEUPOGEN filgrastim VIAL 103353 002 1991-02-20   Start Trial Mediplex Corporation Korea (Seoul, KR) 2039-02-26 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 003 1991-02-20   Start Trial Mediplex Corporation Korea (Seoul, KR) 2039-02-26 RX search
Amgen NEUPOGEN filgrastim SYRINGE 103353 004 1991-02-20   Start Trial Mediplex Corporation Korea (Seoul, KR) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Boehringer Ingelheim
Mallinckrodt
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.